Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


2011: breakthrough year for HIV

28 December 2011, 11:46

The journal Science has chosen the HPTN 052 clinical trial an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year.

The study found that if HIV-infected heterosexual individuals begin taking antiretroviral medicines when their immune systems are relatively healthy as opposed to delaying therapy until the disease has advanced, they are 96% less likely to transmit the virus to their uninfected partners. Findings from the trial, first announced in May, were published in the New England Journal of Medicine.

The complete top 10 list of 2011 scientific breakthroughs appears in the December 23, 2011, issue of Science.

Antiretrovirals treat and prevent HIV

"The HPTN 052 study convincingly demonstrated that antiretroviral medications can not only treat but also prevent the transmission of HIV infection among heterosexual individuals," said NIAID Director Anthony S. Fauci, MD.

"We are pleased that Science recognised the extraordinary public health significance of these study results. This recognition also is a credit to the hard work and dedication of the HPTN 052 researchers and the more than 3 000 study participants who selflessly gave their time and energy to make such a significant contribution to the fight against HIV/Aids."

Led by study chair Myron Cohen, MD, director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, HPTN 052 began in 2005 and enrolled 1 763 heterosexual couples in Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, the United States and Zimbabwe.

Couples randomly assigned 

Each couple included one partner with HIV infection. The investigators randomly assigned each couple to either one of two study groups. In the first group, the HIV-infected partner immediately began taking a combination of three antiretroviral drugs.

The participants infected with HIV were extensively counselled on the need to consistently take the medications as directed. Outstanding compliance resulted in the nearly complete suppression of HIV in the blood (viral load) of the treated study participants in group one.

In the second group (the deferred group), the HIV-infected partners began antiretroviral therapy when their CD4+ T-cell levels - a key measure of immune system health - well below 250 cells per cubic millimetre or an Aids-related event occurred. The HIV-infected participants also were counselled on the need to strictly adhere to the treatment regimen.

The study was slated to end in 2015, but an interim data review in May by an independent data and safety monitoring board (DSMB) found that of the total 28 cases of HIV infection among the previously uninfected partners, only one case occurred among those couples where the HIV-infected partner began immediate antiretroviral therapy. The DSMB, therefore, called for immediate public release of the study's findings.

Combine methods to fight HIV/Aids

The magnitude of protection against HIV infection demonstrated in HPTN 052 has made the successful strategy of the clinical trial a key component of public health policies recently discussed by federal officials and others saying that achieving an end to the HIV/Aids pandemic is now feasible with additional research and implementation efforts.

"On its own, treatment as prevention is not going to solve the global HIV/Aids problem," said Dr Fauci. "Yet when used in combination with other HIV prevention methods - such as knowing one's HIV status through routine testing, proper and consistent condom use, behavioural modification, needle and syringe exchange programs for injection drug users, voluntary, medically supervised adult male circumcision, preventing mother-to-child transmission, and, under some circumstances, antiretroviral use among HIV-negative individuals - we now have a remarkable collection of public health tools that can make a significant impact on the HIV/Aids pandemic."

"Scale-up of these proven prevention methods combined with continued research toward a preventive HIV vaccine and female-controlled HIV prevention tools places us on a path to achieving something previously unimaginable: an Aids-free generation," Dr Fauci added.



Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Submitted by
George Vodongo
Kalonzo says he will defeat UhuRu...

Wiper leader Kalonzo Musyoka has expressed confidence that he will send the Jubilee government home in the upcoming Presidential election. Read more...

Submitted by
S Mbinya
Why Caffeine Is Used for Weight L...

The following are the reasons why caffeine is used for weight loss. Read more...

Submitted by
S Mbinya
What guys want in relationships

Here are the top four things guys need in a relationship. Read more...

Submitted by
EACC recovers KES3.5 million stol...

EACC has recovered KES 3.5 million stolen from Mukurwe-ini Constituency Development Fund (CDF) by former committee members managing the kitty. Read more...

Submitted by
Governor snubs Mashujaa Day celeb...

The Governor was last seen in public during his impeachment debate at Senate, which he survived, and later went India for medical checkups. Read more...

Submitted by
Ben Wangui
President recognises Kenya’s new ...

From young innovators, to doctors and local athletes who have represented Kenya in various events, here are the young heroes recognised by the President in this year's Mashujaa Day celebrations. Read more...